+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

New insights into statin action on the dyslipidemia of type 2 diabetes: normalisation of the plasma lipid profile



New insights into statin action on the dyslipidemia of type 2 diabetes: normalisation of the plasma lipid profile



Atherosclerosis 235(2): E106-E107




Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 064532645

Download citation: RISBibTeXText

DOI: 10.1016/j.atherosclerosis.2014.05.287


Related references

Effects of policosanol and lovastatin on lipid profile and lipid peroxidation in patients with dyslipidemia associated with type 2 diabetes mellitus. International Journal of Clinical Pharmacology Research 22(3-4): 89-99, 2002

Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. Journal of Pediatric Endocrinology and Metabolism 32(4): 327-334, 2019

Statin action favors normalization of the plasma lipidome in the atherogenic mixed dyslipidemia of MetS: potential relevance to statin-associated dysglycemia. Journal of Lipid Research 56(12): 2381-2392, 2015

Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trial. Diabetes Obesity and Metabolism 20(6): 1479-1489, 2018

changes in glycosylated haemoglobin levels among managed care dyslipidemia patients with type 2 diabetes treated with niacin extended-release plus statin versus other lipid therapies. Canadian Journal of Diabetes 33(3): 286-287, 2009

Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes & Metabolism 32(3): 229-235, 2006

The influence of fenofibrate on lipid profile, endothelial dysfunction, and inflammatory markers in type 2 diabetes mellitus patients with typical and mixed dyslipidemia. Journal of Clinical Lipidology 7(5): 446-453, 2014

The efficacy of Ezetimibe added to ongoing Fibrate-Statin therapy on postprandial lipid profile in the patients with type 2 Diabetes mellitus. Journal of Diabetes and Metabolic Disorders 12(1): 24, 2013

Correlation between hemoglobin A1c and serum lipid profile in Afghani patients with type 2 diabetes: hemoglobin A1c prognosticates dyslipidemia. Therapeutic Advances in Endocrinology and Metabolism 8(4): 51-57, 2017

Effect of metformin monotherapy on serum lipid profile in statin-naïve individuals with newly diagnosed type 2 diabetes mellitus: a cohort study. Peerj 6: E4578, 2018

Lipid-altering efficacy and safety profile of combination therapy with ezetimibe/statin vs. statin monotherapy in patients with and without diabetes: an analysis of pooled data from 27 clinical trials. Diabetes Obesity and Metabolism 13(7): 615-628, 2011

A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Molecular Endocrinology 19(6): 1593-1605, 2005

Effects of the age at onset of type 1 diabetes on plasma lipid profile. Journal of the Japan Diabetes Society 47(2): 147-152, 2004

Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination. Casopis Lekaru Ceskych 144(11): 737-741, 2005

New insights into the pathophysiology of dyslipidemia in type 2 diabetes. Atherosclerosis 239(2): 483-495, 2015